Jacobson Center for Clinical & Translational Research

Main Menu

/research/

Additional Information

 

Contact Us

Cardiology Research

Study Title: Zilver® PTX® V: Drug-Eluting Peripheral Stent Post-Approval Study. (Identifier: NCT01901289)

Study Purpose: The Zilver® PTX® V Clinical Study is a post-market clinical trial required by the US FDA to provide continued evaluation of the safety and effectiveness of the Zilver PTX Drug-Eluting Peripheral Stent in treatment of narrowing of the femoropopliteal arteries.

Principal Investigator: Mark Burket, M.D.

Study Coordinator: Stephanie Frank, RN, for more information, please contact 419.383.3853 



Study Title:  A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-M added-on to treprostinil, inhaled (Tyvaso®) in Subjects with Pulmonary Arterial Hypertension (BEAT) (Identifier: NCT01908699)

Study Purpose: Patients new to Tyvaso®, will enter a run-in period on inhaled treprostinil until 90 days of experience is achieved to ensure drug tolerability before enrolling in the study.

Principal Investigator: George Moukarbel, MD

Study Coordinator: Stephanie Frank, RN, for more information, please contact 419.383.3853

 


Study Title: US-based, Observational, Drug Registry Opsumit® (macitentan) new users in clinical practice (OPUS) (Identifier: NCT02126943)

Study Purpose:  Prospective observational drug registry developed to characterize the safety profile (including primarily potential serious hepatic risks) and to describe clinical characteristics and outcomes of patients newly treated with Opsumit® in the post-marketing setting

Principal Investigator: Samer Khouri, M.D.

Study Coordinator: Stephanie Frank, RN, for more information, please contact 419.383.3853

 



 

 

Last Updated: 1/19/16